Mark Dixon

28 days ago

Skinbiotherapeutics: Letter to AIM Regulation, the Ashman “resignation” and Rule 10

We still have  no idea why Stuart Ashman "resigned" fromSkinbiotherapeutics (SBTX) on Thursday night. What we do know is that he had already been suspended by the board as part of an investigation into his conduct. The question AIM Regulation should be asking is when the investigation/suspension started and has the company breached AIM Rule 10. I have written to my pals the Oxymorons at AIM Regulation

63 days ago

Does Mark Dixon know more than me?

As discussed in bearcast earlier, shares in Skinbiotherapeutics (SBTX) may or may not be cheap or expensive. What I neglected to say is that some are arguing that the continued buying by Mark Dixon, he now owns 16.2%, shows that they are cheap: he would not buy so many shares if he did not know something. Hmmmm.